MEDI-1191
- Generic Name
- MEDI-1191
A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 61
- Registration Number
- NCT03946800
- Locations
- 🇪🇸
Research Site, Pamplona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath